Liver cirrhosis in the medical critical care patient

Minerva Anestesiologica

Volumn 78, Issue 6, 2012, Pages 693-703

  Biancofiore, G ^a   Auzinger, G ^b   Mandell, S ^c   Della Rocca, G ^d  

^a UNIVERSITY HOSPITAL OF PISA   (Italy)

^b KING S COLLEGE HOSPITAL   (United Kingdom)

^c UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF UDINE   (Italy)

Author keywords

Critical illness; Intensive care units; Liver cirrhosis

Indexed keywords

ACETYLSALICYLIC ACID; ALBUMIN; ANTIBIOTIC AGENT; BILIRUBIN; CEFTRIAXONE; CREATININE; ENDOTHELIN RECEPTOR ANTAGONIST; ILOPROST; ISOTONIC SOLUTION; N (G) NITROARGININE METHYL ESTER; NORADRENALIN; NORFLOXACIN; OCTREOTIDE; ORNITHINE ASPARTATE; PHOSPHODIESTERASE INHIBITOR; PLACEBO; PLASMA SUBSTITUTE; PROSTACYCLIN; PROSTANOID; RIFAXIMIN; SILDENAFIL; TERLIPRESSIN; UNCLASSIFIED DRUG; UNIPROST; VASOPRESSIN;

ACUTE KIDNEY FAILURE; ALBUMIN DIALYSIS; ASCITES; BLOOD TRANSFUSION; CARDIOVASCULAR DISEASE; CONTINUOUS HEMODIALYSIS; CONTINUOUS INFUSION; CRITICALLY ILL PATIENT; DRUG DOSE ESCALATION; END STAGE LIVER DISEASE; ESOPHAGUS VARICES BLEEDING; FLUID RESUSCITATION; GLOMERULUS FILTRATION RATE; HEPATIC ENCEPHALOPATHY; HEPATOPULMONARY SYNDROME; HEPATORENAL SYNDROME; HUMAN; INFECTION; KIDNEY DYSFUNCTION; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; PORTAL HYPERTENSION; PORTAL VEIN BLOOD PRESSURE; PORTOPULMONARY HYPERTENSION; RESPIRATORY FAILURE; REVIEW; TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT;

BRAIN DISEASES; CRITICAL CARE; CRITICAL ILLNESS; HEART DISEASES; HUMANS; HYPERTENSION, PORTAL; KIDNEY DISEASES; LIVER CIRRHOSIS; LUNG DISEASES;

EID: 84862144697     PISSN: 03759393     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (76)

1. Das V, Boelle YP, Galbois A, Guidet B, Maury E, Carbonell N et al. Cirrhotic patients in the medical intensive care unit: early prognosis and long-term survival. Crit Care Med 2010 38:2108-16.
2. Volk ML, Marrero JA. Advances in critical care hepatology. Minerva Anestesiol 2006;72:269-81.
3. Warrilow SJ. Predictions and outcomes for the critically ill patient with cirrhosis: Is it time to settle on the SOFA and let jaundiced views on outcome MELD away? Crit Care Med 2010;38:259-60.
4. Cholongitasa E, Senzolo M, Patcha M, Shawb S, O'Beirneb J, Burroughsa AK. Cirrhotics admitted to intensive care unit: the impact of acute renal failure on mortality Eur J Gastroenterol Hepatol 2009;21:744-50.
5. D'Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol 2006;44:217-31.
6. Slack A, Yeoman A, Wendon J. Renal dysfunction in chronic liver disease. Crit Care 2010;14:214.
7. Garcia-Tsao G, Parikh CR, Viola A. Acute kidney injury in cirrhosis. Hepatol 2008;48:2064-77.
8. Wong F. Renal diseases and the liver. Clin Liver Dis 2011;15:39-53.
9. Meltzer J, Brentjens TE. Renal failure in patients with cirrhosis: hepatorenal syndrome and renal support strategies. Curr Opin Anaesth 2010;23:139-44.
10. Wong F, Nadim MK, Kellum KA, Salerno F, Bellomo R, Gerbes A et al. Working party proposal for a revised classification system of renal dysfunction in patients with cirrhosis. Gut 2011;60:702-9.
11. Biancofiore G, Davis CL. Renal dysfunction in the perioperative liver transplant period. Curr Opin Organ Transplant 2008;13:291-7.
12. Davemport A. Difficulties in assessing renal function in patients with cirrhosis: potential impact on patient treatment. Intensive Care Med 2011;37:930-2.
13. Hasper D, Jorres J. New insights into the management of hepato-renal syndrome. Liver Int 2011;31(Suppl. 3):27-30.
14. Narahara Y, Kanazawa H, Taki Y, Kimura Y, Atsukawa M, Katakura T et al. Effects of terlipressin on systemic, hepatic and renal hemodynamics in patients with cirrhosis. J Gastroenterol Hepatol 2009;24:1791-7.
15. Rajekar H, Chawla Y. Terlipressin in hepatorenal syndrome: evidence for present indications. J Gastroenterol Hepatol 2011;26;109-14.
16. Sagi SV, Mittal S, Kasturi KS, Sood GK. Terlipressin therapy for reversal of type 1 hepatorenal syndrome: a meta-analysis of randomized controlled trials. Gastroenterol Hepatol 2010;25:880-5.
17. Gerbes AL, Huber E, Gulberg V. Terlipressin for hepatorenal syndrome: continuous infusion as an alternative to iv bolus administration. Gastroenterology 2009;137:1179-81.
18. Kiser TH, MacLaren R, Fish DN. Treatment of hepatorenal syndrome. Pharmacotherapy 2009;29:1196-211.
19. Wong F, Raina N, Richardson R. Molecular adsorbent recirculating system is ineffective in the management of type 1 hepatorenal syndrome in patients with cirrhosis with ascites who have failed vasoconstrictor treatment. Gut 2010;59:381-6.
20. Bosch J, Abraldes JG, Berzigotti A, García-Pagan JC. The clinical use of HVPG measurements in chronic liver disease. JC Nat Rev Gastroenterol Hepatol 2009;6:573-82.
21. Garcia-Tsao G, Sanyal AJ, Grace ND, Carey Wand the Practice Guidelines Committee of the American Association for the Study of Liver Diseases, the Practice Committee of the American College of Gastroenterology. Hepatology 2007;46:922-93817.
22. Perelló A, Escorsell A, Bru C, Gilabert R, Moitinho E, García-Pagán JC et al. Wedge hepatic venous pressure adequately reflects portal pressure in hepatitis C virus-related cirrhosis. Hepatology 1999;30:1393-7.
23. Mookerjee RP. Acute-on chronic liver failure: the liver and portal hemodynamic. Curr Opin Crit Care 2011;17:170-6.
24. de Franchis R on behalf of the Baveno V. Faculty revising consensus in portal hypertension: report of the Baveno V consensus workshop on methodology of diagnosis and therapy in portal hypertension. Journal of Hepatology 2010;53: 762-8.
25. de Franchis R. Evolving consensus in portal hypertension report of the Baveno IV consensus workshop on methodology of diagnosis and therapy in portal hypertension. J Hepatol 2005;43:167-76.
26. Harry R, Wendon J. Management of variceal bleeding. Opin Crit Care 2002;8:164-70.
27. Thalheimer U, Triantos C, Goulis J, Burroughs A. Management of varices in cirrhosis. Expert Opin Pharmacother 2011;12:721-35.
28. Abid S, Jafri W, Hamid S, Salih M, Azam Z, Mumtaz K et al. Terlipressin vs. octreotide in bleeding esophageal varices as an adjuvant therapy with endoscopic band ligation: a randomized double-blind placebo-controlled trial. Am J Gastro-Gastroenterol 2009;104:617-23.
29. Rahimi RS, Rockey DC. Complications and outcomes in chronic liver disease. Curr Opin Gastroenterol 2011;27:204-9.
30. Al-Khafaji A, Huang DT. Critical care management of patients with end-stage liver disease. Crit Care Med 2011;39: 1157-66.
31. Boyer TD, Haskal ZJ. AASLD Practice Guidelines: the role of trans-jugular intrahepatic porto-systemic shunt (TIPS) in the management of portal hypertension: update 2009. Hepatology 2010;51:306-11.
32. Vangeli M, Patch D, Burroughs AK. Salvage tips for uncontrolled variceal bleeding. J Hepatol 2002;37:703-4.
33. Hou MC, Lin HC, Liu TT, Kuo BI, Lee FY, Chang FY et al. Antibiotic prophylaxis after endoscopic therapy prevents rebleeding in acute variceal hemorrhage: a randomized trial. Hepatology 2004;39:746-53.
34. Fernández J, Ruiz del Arbol L, Gpomez C, Durandez R, Serradilla R et al. Norfloxacin vs. ceftriaxone in the prophylaxis of infections in patients with advanced cirrhosis and hemorrhage. Gastroenterology 2006;131:1049-56.
35. Salerno F, Guevara M, Bernardi M, Moreau R, Wong F, Angeli P et al. Refractory ascites: pathogenesis, definition and therapy of severe complication in patients with cirrhosis. Liver Int 2010;30:937-47.
36. European association for the study of the liver. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol 2010;53:397-417.
37. Cheruvattath R, Balan V. Infections in patients with end-stage liver disease. J Clin Gastrenerol 2007;41:403-11.
38. Viasus D, Garcia-Vidal C, Castellote J, Adamuz J, Verdaquer R, Dorca J et al. Community-acquired pneumonia in patients with liver cirrhosis: clinical features, outcomes, and usefulness of severity scores. Medicine 2011;90:110-8.
39. Lim LG, Tan XX, Woo SJ, Dan YY, Lai V, Lim SG. Risk factors for mortality in cirrhotic patients with sepsis. Hepatol Int 2011 [E-pub ahead of print].
40. Kang CI, Song JH, Ko KS, Chung DR, Peck KE, Asian Network for Surveillance of Resistant Pathogens (ANSORP) Study Group. Clinical signficance of Staphylococcus aureus infection in patients with chronic liver disease. Liver Int 2010;9:1333-8.
41. Propst-Graham KL, Preheim LC, Vander EA, Snitily MJ, Gentry-Nielsen MJ. Cirrhosis-induced defects in innate pulmonary defenses against Streptococcus pneumonia. BMC Microbiol 2007;7:94. l
42. Loke YK, Kwok CS, Niruban A, Myint PK. Value of severity scales in predicting mortality from community-acquired pneumonia: systematic review and meta-analysis. Thorax 2010;66:383-8.
43. Benson AB, Burton JR, Austin GL, Biggins SW, Zimmerman MA, Kam I et al. Differential effects of plasma and red blood cell transfusions on acute lung injury and infection risk following liver transplantation. Liver Transpl 2010;17:149-58.
44. Li G, Rachmale S, Kojicic M, Shahjehan K, Malinchoc M, Kor DJ, Gajic O. Incidence and transfusion risk factors for transfusion-associated circulatory overload among medical intensive care unit patients. Transfusion 2011;51:338-43.
45. Endimiani A, Hujer KM, Hujer AM, Kurz S, Jacobs MR, Perlin DS et al. Are we ready for novel detection methods to treat respiratory pathogens in hospital-acquired pneumonia? Clin Infect Dis 2011;52(Suppl):S373-82.
46. Kochar R, Nevah Rubin MI, Fallon MB. Pulmonary complications of cirrhosis. Curr Gastroenterol Rep 2011;13:34-9.
47. Rodríguez-Roisin R, Krowka MJ, Hervé P, Fallon MB; ERS Task Force Pulmonary-Hepatic Vascular Disorders (PHD) Scientific Committee. Pulmonary hepatic vascular disorders. Eur Respir J 2004;24:861-80.
48. El-Shabrawi MH, Omran S, Wageeh S, Isa M, Okasha S, Mohsen NA et al. (99m)Technetium-macroaggregated albumin perfusion lung scan versus contrast enhanced echocardiography in the diagnosis of the hepatopulmonary syndrome in children with chronic liver disease. Eur J Gastroenterol Hepatol 2010;22:1006-12.
49. Gupta D, Vijaya DR, Gupta R, Dhiman RK, Bhargava M, Verma J et al. Prevalence of hepatopulmonary syndrome in cirrhosis and extrahepatic portal venous obstruction. Am J Gastroenterol 2001;96:3395-9.
50. Abrams GA, Sanders MK, Fallon MB. Utility of pulse oximetry in the detection of arterial hypoxemia in liver transplant candidates. Liver Transpl 2002;8:391-6.
51. Bozbas SS, Eyuboglu F. Evaluation of liver transplant candidates: A pulmonary perspective. Ann Thorac Med 2011;6:109-14.
52. Gómez FP, Martínez-Pallí G, Barberà JA, Roca J, Navasa M, Rodríguez-Roisin R. Gas exchange mechanism of orthodeoxia in hepatopulmonary syndrome. Hepatology 2004;40:660-6.
53. Khan AN, Al-Jahdali H, Abdullah K, Irion KL, Sabih Q, Gouda A. Pulmonary vascular complications of chronic liver disease: Pathophysiology, imaging, and treatment. Ann Thorac Med 2011;6:57-65.
54. Møller S, Hobolth L, Winkler C, Bendtsen F, Christensen E. Determinants of the hyperdynamic circulation and central hypovolaemia in cirrhosis. Gut 2011;60:1254-9.
55. Singh V, Ghosh S, Singh B, Kumar P, Sharma N, Bhalla A et al. Noradrenaline vs. terlipressin in the treatment of hepatorenal syndrome: A randomized study. J Hepatol 2012 [Epub ahead of print].
56. Flynn A, Chokkalingam Mani B, Mather PJ. Sepsis-induced cardiomyopathy: a review of pathophysiologic mechanisms. Heart Fail Rev 2010;15:605-11.
57. Sado D, Greaves K. Myocardial perfusion echocardiography: a novel use in the diagnosis of sepsis-induced left ventricular impairment on the intensive care unit. Eur J Echocardiogr 2011;12:81-4.
58. Marcelino PA, Marum SM, Fernandes AP, Germano N, Lopes MG. Routine transthoracic echocardiography in a gen-general intensive care unit: an 18 month survey in 704 patients. Eur J Intern Med 2000;20:c37-c42.
59. Chockalingam A, Mehra A, Dorairajan S, Dellsperger K. Acute left ventricular dysfunction in the critically ill. Chest 2010;138:198-07.
60. Saleen S. Portopulmonary hypertension. Ann Thorac Med 2010;5:5-9.
61. Giusca S, Jinga M, Jurcut C, Jurcut R, Serban M, Ginghina C. Portopulmonary hypertension: from diagnosis to treatment. Eur J Intern Med 2011;22:441-7.
62. Savale L, O'Callaghan DS, Magnier R, Le Pavec J, Hervé P, Jaïs X, Seferian A et al. Current management approaches to portopulmonary hypertension. Int J Clin Pract Suppl 2011;169:11-8.
63. Bernal W, Hall C, Karvellas C, Auzinger G, Sizer E, Wendon J. Arterial ammonia and clinical risk factors for encephalopathy and intracranial hypertension in acute liver failure. Hepatology 2007;46:1844-52.
64. Conn H, Lieberthal M. The hepatic coma syndromes and lactulose. Baltimore, MD: Williams and Wilkins; 1979.
65. Klempnaue J, Schrem H. Surgical shunts and encephalopathy. Metab Brain Dis 2001;16:21-5.
66. Riggio O, Merli M, Pedretti G, Servi R, Meddi P, Lionetti R et al. Hepatic encephalopathy after transjugular intrahepatic portosystemic shunt. Incidence and risk factors. Dig Dis Sci 1996;41:578-84.
67. Riggio O, Efrati C, Catalano C, Pediconi F, Mecarelli O, Accornero N et al. High prevalence of spontaneous portal-systemic shunts in persistent hepatic encephalopathy: a case-control study. Hepatology 2005;42:1158-65.
68. Riggio O, Angeloni S, Salvatori FM, De Santis A, Cerini F, Farcomeni A et al. Incidence, natural history, and risk factors of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt with polytetrafluoroethylenecovered stent grafts. Am J Gastroenterol 2008;103:2738-46.
69. Uribe M, Campollo O, Vargas F, Ravelli GP, Mundo F, Zapata L et al. Acidifying enemas (lactitol and lactose) vs. Non-acidifying enemas (tap water) to treat acute portalsystemic encephalopathy: a double-blind, randomized clinical trial. Hepatology 1987;7:639-43.
70. Cordoba J, Alonso J, Rovira A, Jacas C, Sanpedro F, Castells L et al. The development of low-grade cerebral oedema in cirrhosis is supported by the evolution of 1H-magnetic resonance abnormalities after liver transplantation. J Hepatol 2001;35:598-604.
71. Shawcross DL, Shabbir SS, Taylor NJ, Hughes RD. Ammonia and the neutrophil in the pathogenesis of hepatic encephalopathy in cirrhosis. Hepatology 2010;51:1062-9.
72. Angeli P, Wong F, Watson H, Gines P. Hyponatremia in cirrhosis: results of a patient population survey. Hepatology 2006;44:1535-42.
73. Jalan R, Kapoor D. Enhanced renal ammonia excretion following volume expansion in patients with well compensated cirrhosis of the liver. Gut 2003;52:1041-5.
74. Acharya SK, Bhatia V, Sreenivas V, Khanal S, Panda SK. Efficacy of L-ornithine L-aspartate in acute liver failure: a double-blind, randomized, placebo-controlled study. Gastroenterology 2009;136:2159-68.
75. Bass NM, Mullen KD, Sanyal A, Poordad F, Neff G, Leevy CB et al. Rifaximin treatment in hepatic encephalopathy. N Engl J Med 2010;362:1071-81.
76. Hassanein TI, Tofteng F, Brown RS Jr, McGuire B, Lynch P, Mehta R et al. Randomized controlled study of extracorporeal albumin dialysis for hepatic encephalopathy in advanced cirrhosis. Hepatology 2007;46:1853-62.